"It’s hard to see why we wouldn't reach a billion kroner this year"
The Danish parallel importer Abacus Medicine delivered impressive revenue growth in 2015 as well, and according to CEO Flemming Wagner the growth will continue in 2016. The company continues to invest heavily in new markets as the Danish market remains challenging.
.jpg)
BY STEFAN SINGH KAILAY
The impressive growth rates continue at Danish parallel importer Abacus Medicine. According to the recently published annual report for 2015, revenue rose by an entire 33.4 percent to USD 127.5 million (DKK 834.5 million). Abacus has delivered yearly growth rates of more than 27 percent since 2011, where revenue sat at USD 43.2 million (DKK 283.1 million) and according to CEO Flemming Wagner, this growth is attributed to intensive investments.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
DHL banks on life science
For abonnenter
UnitedHealth-acquisition could cause US price hikes
For abonnenter
Soaring orphan drug prices rule global agenda
For abonnenter
